New Anti-Epileptic Drug Formulations Try To Overcome Tolerability Problems
This article was originally published in Pharmaceutical Approvals Monthly
Much of the drug development activity in epilepsy is focused on improving the existing treatments.
You may also be interested in...
Dainippon subsidiary plans to launch its next-generation version of carbamazepine in the second half of 2014. Lack of classification as a controlled substance means more direct access to prescribers, company says.
Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.